Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

Pathway raises $40 mil. to boost atherectomy catheter roll out: Maker of the Jetstream G2 peripheral atherectomy catheter raises $40 million in a private placement announced March 30. Pathway Medical Technologies will use the proceeds "to continue to build its sales team, grow its manufacturing organization, continue product development and prepare for profitability," the firm says. Jetstream G2 gained 510(k) clearance Jan. 13 "for use in atherectomy of the peripheral vasculature," according to FDA. The device subsequently gained expanded clearance "specifically for use in breaking apart and removing thrombus (or blood clots) from the upper and lower extremity peripheral arteries," the Kirkland, Wash.-based company reported March 23. Jetstream G2 "offers specific design enhancements to Pathway's first-generation device," cleared in October 2008, the firm notes. Until now, peripheral atherectomy devices "have not been effective in removing all types of hard and soft tissue plaque," Pathway claims. Contributors to the latest financing round include Forbion Capital Partners, HLM Venture Partners, Latterell Venture Partners, Oxford Bioscience Partners and Giza Venture Capital
Advertisement

Related Content

Research In Brief
Research In Brief

Topics

Advertisement
UsernamePublicRestriction

Register

MT027290

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel